Medical technology company iSonea Limited has received a US innovation award for its AsthmaSense Cloud mobile health technology.
The North American Frost and Sullivan 2013 Innovation Leadership Award 2013 acknowledges iSonea’s “outstanding achievement” and superior performance in developing an innovative product featuring leading-edge technologies.
Announcing the award, F&S described iSonea as “A pioneer in the healthcare industry”, commending the product’s ability to easily collect, analyse and communicate asthma data and noting the company’s leadership, innovation, customer service and strategic product development.
Frost and Sullivan industry analyst Vin Lee Nim said, “AsthmaSense app and AsthmaSense Cloud's data compilation of users’ asthma events clearly illustrates the ‘cause and effect’ by mapping the lifestyle, environmental, and physiological causes of asthma attacks.” “AsthmaSense app’s programmable reminders and alerts can potentially improve patient adherence to asthma management. This can lead to more diligent monitoring of risks in real-life settings.”
iSonea CEO Michael Thomas said the award was outstanding recognition for the Company’s trend-setting mobile health technologies. “This award recognises the proprietary technology and innovative design underpinning our products,” he said. “We are extremely proud of our AsthmaSense app and the accompanying Cloud technology, which was a first-in-class advancement in the mobile health asthma market. We are now taking this a step further and will launch our next generation product, the AirSonea, in Australia within weeks. AirSonea will signal a new age in asthma monitoring via cutting edge mobile health technologies and enhanced patient empowerment for rapid identification and quantification of wheeze.”
The AsthmaSense mobile app tracks asthma symptoms (signs of breathing function, medication usage) and the treatment plan. Used in conjunction with the company’s proprietary Acoustic Respiratory Monitoring (ARM) system, the app is evolving to integrate wheeze monitoring into the risk-sensing equation, as well as the user’s geographical location, weather, and air quality factors that may affect asthma patients.
Linking the AsthmaSense Cloud with the AsthmaSense app enables the asthma event monitoring data to automatically store patient data and responses in a password-protected cloud vault transfer. AsthmaSense app’s programmable reminders and alerts can potentially improve patient adherence to asthma management. This can lead to more diligent monitoring of risks in real-life settings. The AirSonea device will enable real-time, objective wheeze rate monitoring via smartphone for the first time globally.
iSonea Limited is developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD.